Effect of CPP-ACP on Oral Health of Cerebral Palsy Children

Objective: The aim of this study was to evaluate the effect of Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP) on buffering capacity of saliva and plaque pH in individuals with cerebral palsy (CP). Methods: 15 children with CP were included, (mean age: 5.6±2) who lived in a goverment institution in Istanbul, Turkey. Before using CPP-ACP complex, buffering capacities of saliva and plaque were checked in first measurement and accepted as control group. Then, CPP-ACP complex (GC Tooth Mouse, Recaldent™, GC Corp., Tokyo, Japan) applied to the children two times a day regularly by caretakers. Saliva and plaque samples were collected with using plastic strips and tubes. Dental plaque pH and buffering capacity of saliva were measured by using Saliva-Check Buffer (GC Corp., Tokyo, Japan) and Plaque Indicator Kit (GC Dental Corp., Japan). Measurements were repeated on 1st, 2nd, 3rd, 4th, 6th and 8th weeks. All scores were assessed according to manufacturer's instructions. All the data was analyzed statistically by Dunn's multiple comparison, Friedman and Mc Nemar's tests. Results: For plaque pH, although there were no significant differences between the initial and the 1st, 2nd and 3rd weeks' scores (p>0,05); statistically significant differences were seen between initial and 4th, 6th and 8th weeks' scores (p=0,039,p=0,042,p=0,018). For buffering capacity of saliva, a significant difference was seen between the initial and the 1st, 2nd, 3th, 4th, 6th and 8th weeks' scores (p=0,0001). The 1st and 2nd weeks' saliva buffer scores significantly lower than 6th and 8th weeks' scores (p=0,003,p=0,001). No significant differences were found in other time points(p=0,0001). Conclusions: From the result of this study, it was suggested that CPP-ACP complex is efective on saliva buffering capacity and plaque pH; therefore it may be a good choice as CP individuals generally need high oral hygiene attention.